A Genome Sequence for the Accidental Antibiotic: related news

A Genome Sequence for the Accidental Antibiotic

BBC reports that Dutch researchers at DSM Anti-Infectives have sequenced the genome of Penicillium chrysogenum, the fungus that produces penicillin. The sequence will be published in Nature Biotechnology this October, and researchers say its availability may help scientists develop antibiotics to deal with drug-resistant bacterial strains such as MRSA.

First Whole Cancer Genome Sequenced

dooling writes "A paper detailing the sequencing of the first human cancer genome will be published in the 6 November 2008 issue of Nature. This is not only the first cancer genome published, it is the first female genome as well. You can read the paper's abstract, DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome, or the story in Science News. This issue of Nature also has articles on the sequencing of the first African and Asian genomes. The sequencing in all three articles was done using the Illumina Genome Analyzer, one of the massively parallel, next-generation genome sequencing platforms."

Genome Institute of Singapore Purchases Four Additional Illumina Genome Analyzers to Advance Stem Cell and Cancer Research Studies

SAN DIEGO--(BUSINESS WIRE)--Oct 9, 2008 - Illumina, Inc. (NASDAQ:ILMN) today announced that the Genome Institute of Singapore (GIS), a flagship institution of Singapore and one of the top research centers in the world, has purchased four additional Genome Analyzers taking its installed base to six. Among researchers at GIS, the Genome Analyzer continues to be the preferred platform for conducting sequencing studies. The Genome Analyzers will be used in a variety of projects, including the construction of transcriptional networks linked to cancer and stem cells.

Scientists sequence genome of a cancer patient

Add our medical news to StumbleUpon - Scientists sequence genome of a cancer patient Add our medical news to Facebook - Scientists sequence genome of a cancer patient

Researcher sequence genome of cancer patient

For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots. A large research team at the Genome Sequencing Center and the Siteman Cancer Center at Washington University School of Medicine in St. Louis sequenced the genome of the patient - a woman in her 50s who ultimately died of her disease - and the genome of her leukemia cells, to identify genetic changes unique to her cancer.

Scientists Sequence First Genome Of Cancer Patient

Scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots. A large research team at the Genome Sequencing Center and the Siteman Cancer Center at Washington University School of Medicine in St. Louis sequenced the genome of the patient - a woman in her 50s who ultimately died of her disease - and the genome of her leukemia cells, to identify genetic changes unique to her cancer.

Genome of a monkey-human malaria parasite: surprises from Plasmodium knowlesi genome sequence

Researchers have decoded the genome of a malaria parasite that has a host range from monkeys to man. Identified originally in monkeys, the parasite was first reported in a human infection just over 40 years ago.

Illumina's human genome sequencing studies published in Nature

Illumina announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies. This marks the first time that three human genome studies--including the first Asian individual, the first cancer patient, and the first African male--have been simultaneously publis

Illumina Announces Breakthrough Human Genome Sequencing Studies Published in Nature

Three Landmark Studies of Independent Human Genomes Carried Out on Illumina Genome Analyzer SAN DIEGO--(Business Wire)-- Illumina (NASDAQ: ILMN) today announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies.

Illumina Announces Breakthrough Human Genome Sequencing Studies Published in Nature

today announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies. This marks the first time that three human genome studies--including the first Asian individual, the first cancer patient, and the first African male--have been simultaneously published

Illumina Announces Breakthrough Human Genome Sequencing Studies Published in Nature

Illumina (NASDAQ: ILMN) today announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies. This marks the first time that three human genome studies--including the first Asian individual, the first cancer patient, and the first African male--have been

Illumina Announces Breakthrough Human Genome Sequencing Studies Published in Nature

SAN DIEGO--(BUSINESS WIRE)--Nov 7, 2008 - Illumina (NASDAQ: ILMN) today announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies. This marks the first time that three human genome studies--including the first Asian individual, the first cancer patie

Genome Institute of Singapore Purchases Four Additional Illumina Genome Analyzers to Advance Stem Cell and Cancer Research Studies

Genome Institute of Singapore Purchases Four Additional Illumina Genome Analyzers to Advance Stem Cell and Cancer Research Studies

Genome Institute of Singapore Purchases Four Additional Illumina Genome Analyzers to Advance Stem Cell and Cancer Research Studies

Genome Institute of Singapore Purchases Four Additional Illumina Genome Analyzers to Advance Stem Cell and Cancer Research Studies

Genome Institute of Singapore Purchases Four Additional Illumina Genome Analyzers to Advance Stem Cell and Cancer Research Studies

Genome Institute of Singapore Purchases Four Additional Illumina Genome Analyzers to Advance Stem Cell and Cancer Research Studies

The Wellcome Trust Sanger Institute Continues Scale Up with Order for 11 Additional Illumina Genome Analyzers

SAN DIEGO--(BUSINESS WIRE)--Nov 13, 2008 - Illumina, Inc. (NASDAQ:ILMN) today announced that the Wellcome Trust Sanger Institute has purchased 11 additional Genome Analyzers, increasing the organization's total number of the Illumina sequencing platform to 37. The continued scale up on the Genome Analyzer will support the Sanger Institute's many initiatives, such as its contribution to the 1000 Genome Project, which requires economical, accurate, and rapid sequence generation.

Genome Institute of Singapore purchases 4 additional Illumina Genome Analyzers for stem cell, cancer research studies - Quick Facts

(RTTNews) - Illumina, Inc. (ILMN: News ) announced that the Genome Institute of Singapore has purchased four additional Genome Analyzers taking its installed base to six.

Genome Institute of Singapore Purchases Four Additional Illumina Genome Analyzers to Advance Stem Cell and Cancer Research Studies

SAN DIEGO - Illumina, Inc. (NASDAQ:ILMN) today announced that the Genome Institute of Singapore (GIS), a flagship institution of Singapore and one of the top research centers in the world, has purchased four additional Genome Analyzers taking its installed base to six. Among researchers at G

Scientists sequence woolly-mammoth genome

Penn State genomicists Webb Miller and Stephan C. Schuster in front of the Roche / 454 Life Sciences' Genome Sequencer 20 System that was used to sequence mammoth nuclear DNA.

JCVI Researchers Collaborate on Sequence and Analysis of First Pennate Diatom Genome

PRNewswire-USNewswire/ -- The genome of Phaeodactylum tricornutum has been sequenced and analyzed by a large international team of researchers led by U.S. Department of Energy Joint Genome Institute (DOE JGI) and the Ecole Normale Superieure of

Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project

ANN ARBOR, Mich., Oct. 13 /PRNewswire/ -- Rubicon Genomics, Inc. today announced an agreement with SAIC-Frederick to amplify DNA samples for The Cancer Atlas Genome Project. Rubicon Genomics was selected to amplify and standardize total genomic DNA from 3,000 tissue and blood samples from cancer patients. The Rubicon GenomePlex(TM) Whole Genome Amplification technology was judged best to amplify clinical DNA samples to the constant concentration and quality necessary for reproducible and accurate analysis using microarrays and PCR. The amplified DNA libraries will be deposited into the International Genomics Consortium Biospecimen Research Core as a renewable resource to be shared among international researchers to completely characterize the genomes of patients with three types of cancer.

JCVI Researchers Collaborate on Sequence and Analysis of First Pennate Diatom Genome

LA JOLLA, Calif., Oct. 15 /PRNewswire-USNewswire/ -- The genome of Phaeodactylum tricornutum has been sequenced and analyzed by a large international team of researchers led by U.S. Department of Energy Joint Genome Institute (DOE JGI) and the Ecole Normale Superieure of Paris. The group also includes scientists from the J. Craig Venter Institute. The team was led by first author Chris Bowler, Ph.D., of the Ecole Normale Superieure, and published results in the October 15 edition of Nature. This is only the second diatom and the first of the pennate class to be sequenced and published.

U.S. researchers decode first complete genome sequence of a cancer

Technology news and Jobs arrow Science arrow U.S. researchers decode first complete genome sequence of a cancer

10 Pioneers receive genome data in phase-one of Personal Genome Project

BOSTON, Mass. (Oct. 20, 2008) —Ten individuals, many of them world renowned researchers, reviewed—and in most cases released—partial coding region data of their genomes in the first phase of a major initiative to make personal genome sequencing more affordable and accessible. The Personal Genome Project (PGP), led by Harvard Medical School geneticist George Church, will serve as a test-bed for new DNA sequencing technologies and a resource for researchers probing the genetic basis of diseases and other traits.

Search took 0.06 seconds.